Related Experiment Video
Updated: Mar 3, 2026
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film
Cem Varan1, Henrika Wickström2, Niklas Sandler2
1Department of Nanotechnology and Nanomedicine, Graduate School of Science and Engineering, Hacettepe University, Ankara, Turkey.
Abstract:
Personalized medicine is an important treatment approach for diseases like cancer with high intrasubject variability. In this framework, printing is one of the most promising methods since it permits dose and geometry adjustment of the final product. With this study, a combination product consisting of anticancer (paclitaxel) and antiviral (cidofovir) drugs was manufactured by inkjet printing onto adhesive film for local treatment of cervical cancers as a result of HPV infection. Furthermore, solubility problem of paclitaxel was overcome by maintaining this poorly soluble drug in a cyclodextrin inclusion complex and release of cidofovir was controlled by encapsulation in polycaprolactone nanoparticles. In vitro characterization studies of printed film formulations were performed and cell culture studies showed that drug loaded film formulation was effective on human cervical adenocarcinoma cells. Our study suggests that inkjet printing technology can be utilized in the development of antiviral/anticancer combination dosage forms for mucosal application. The drug amount in the delivery system can be accurately controlled and modified. Moreover, prolonged drug release time can be obtained. Printing of anticancer and antiviral drugs on film seem to be a potential approach for HPV-related cervical cancer treatment and a good candidate for further studies.
Insights
Inkjet printing created a novel film combining anticancer and antiviral drugs for HPV-related cervical cancer. This personalized medicine approach offers controlled drug delivery and effective treatment for cervical adenocarcinoma cells.
Area of Science:
- Pharmaceutical Technology
- Oncology
- Virology
Background:
- Personalized medicine addresses cancer's high intrasubject variability.
- Inkjet printing allows precise dose and geometry control for drug delivery systems.
- Human Papillomavirus (HPV) infection is a primary cause of cervical cancer.
Purpose of the Study:
- To develop a combination dosage form of paclitaxel (anticancer) and cidofovir (antiviral) using inkjet printing.
- To create a localized treatment for cervical cancer via an adhesive film for mucosal application.
- To overcome paclitaxel's solubility issues and control cidofovir release.
Main Methods:
- Paclitaxel was formulated into a cyclodextrin inclusion complex to enhance solubility.
- Cidofovir was encapsulated in polycaprolactone nanoparticles for controlled release.
- Inkjet printing was employed to deposit the drug formulations onto an adhesive film.
- In vitro characterization and cell culture studies were performed on the printed formulations.
Main Results:
- The inkjet-printed film successfully incorporated both paclitaxel and cidofovir.
- Formulations demonstrated effective action against human cervical adenocarcinoma cells in vitro.
- The study confirmed the feasibility of inkjet printing for creating combination antiviral/anticancer dosage forms.
- Controlled drug release and accurate drug loading were achieved.
Conclusions:
- Inkjet printing is a viable technology for developing localized, combination drug delivery systems for mucosal application.
- This approach shows potential for treating HPV-related cervical cancer with improved drug control and prolonged release.
- The developed film formulation is a promising candidate for further investigation in cervical cancer therapy.
